Upstream Bioprocess for Adenovirus Vectors

Abstract Adenovirus vectors (AdV) constitute very powerful vehicles for gene transfer with applications in vaccination, cancer treatment, and many monogenic and acquired diseases. To cope with the need for significant amounts of clinical grade material, efficient and robust bioprocesses compliant with good manufacturing practices need to be established. This chapter reviews AdV production processes, discussing how producer cell line specifications, viral construction, cell culture characteristics, and bioprocess parameters can impact the overall production yields. Further considerations for upstream processing to meet the specifications for clinical product release are also presented in this chapter. Finally, future directions toward a simplified and streamlined production process are discussed in light of state-of-the-art AdV manufacturing.

[1]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[2]  S. Tyack,et al.  Antibody fragments, expressed by a fowl adenovirus vector, are able to neutralize infectious bursal disease virus , 2010, Avian pathology : journal of the W.V.P.A.

[3]  M. Havenga,et al.  Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. , 2006, The Journal of general virology.

[4]  F. Graham,et al.  Development of a FLP/frt system for generating helper-dependent adenoviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  S. Swaminathan,et al.  Regulation of adenovirus E2 transcription unit. , 1995, Current topics in microbiology and immunology.

[6]  B. Walker,et al.  Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1 , 2005, The Journal of Immunology.

[7]  E. Nagy,et al.  A region at the left end of the fowl adenovirus 9 genome that is non-essential in vitro has consequences in vivo. , 2010, The Journal of general virology.

[8]  E. Galanis,et al.  Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress , 2007, Nature Clinical Practice Oncology.

[9]  A. van der Eb,et al.  New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. , 1998, Human gene therapy.

[10]  M. Perrier,et al.  Metabolic flux analysis of HEK-293 cells in perfusion cultures for the production of adenoviral vectors. , 2005, Metabolic engineering.

[11]  Michel Perrier,et al.  Insights into adenoviral vector production kinetics in acoustic filter‐based perfusion cultures , 2004, Biotechnology and bioengineering.

[12]  W. Doerfler,et al.  The Molecular Repertoire of Adenoviruses I , 1995, Current Topics in 199/I Microbiology and Immunology.

[13]  E. B. Butler,et al.  Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  M. Rudnicki,et al.  A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Kamen,et al.  Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells , 2004, Cytotechnology.

[16]  M. Lusky,et al.  In Vitro and In Vivo Biology of Recombinant Adenovirus Vectors with E1, E1/E2A, or E1/E4 Deleted , 1998, Journal of Virology.

[17]  K. Spindler,et al.  Analysis of early region 3 mutants of mouse adenovirus type 1 , 1996, Journal of virology.

[18]  S. Mittal,et al.  Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. , 2004, Virus research.

[19]  A. Beaudet,et al.  Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery. , 1998, Human gene therapy.

[20]  S. Tikoo,et al.  Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines. , 2002, Virology.

[21]  A. Kamen,et al.  Overview of current scalable methods for purification of viral vectors. , 2011, Methods in molecular biology.

[22]  J. Wilson,et al.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy , 1996, Journal of virology.

[23]  E. De Clercq,et al.  Mouse Adenovirus Type 1 Infection in SCID Mice: an Experimental Model for Antiviral Therapy of Systemic Adenovirus Infections , 2005, Antimicrobial Agents and Chemotherapy.

[24]  E. Bridge,et al.  Redundant control of adenovirus late gene expression by early region 4 , 1989, Journal of virology.

[25]  M. Perrier,et al.  From the first to the third generation adenoviral vector: what parameters are governing the production yield? , 2009, Biotechnology advances.

[26]  B. Delmas,et al.  Construction of Avian Adenovirus CELO Recombinants in Cosmids , 2001, Journal of Virology.

[27]  A. Berk.  Adenovirus promoters and E1A transactivation. , 1986, Annual review of genetics.

[28]  J. H. Kim,et al.  A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. , 1998, Human gene therapy.

[29]  B. Davidson,et al.  Factors that influence stability of recombinant adenoviral preparations for human gene therapy. , 1998, Pharmaceutical development and technology.

[30]  Alois Jungbauer,et al.  Continuous downstream processing of biopharmaceuticals. , 2013, Trends in biotechnology.

[31]  F. Paillard.  Advantages of Non-Human Adenoviruses Versus Human Adenoviruses Promoter Attenuation in Gene Therapy: Causes and Remedies , 1997 .

[32]  P. Lowenstein,et al.  Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  M. Metzker,et al.  Optimization of the helper-dependent adenovirus system for production and potency in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  E. Moran.  DNA tumor virus transforming proteins and the cell cycle. , 1993, Current opinion in genetics & development.

[35]  E. Schaefer,et al.  Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector. , 1999, Human gene therapy.

[36]  W. Schaffner,et al.  The nucleotide sequence and a first generation gene transfer vector of species B human adenovirus serotype 3 , 2005, Virology.

[37]  S. Mittal,et al.  Current strategies and future directions for eluding adenoviral vector immunity. , 2006, Current gene therapy.

[38]  E. White,et al.  Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. , 1993, Genes & development.

[39]  M. Perrier,et al.  293SF Metabolic Flux Analysis during Cell Growth and Infection with an Adenoviral Vector , 2000, Biotechnology progress.

[40]  F. Blanche,et al.  An improved anion-exchange HPLC method for the detection and purification of adenoviral particles , 2000, Gene Therapy.

[41]  L. Gooding,et al.  Prevalence and Quantitation of Species C Adenovirus DNA in Human Mucosal Lymphocytes , 2002, Journal of Virology.

[42]  James M. Wilson,et al.  Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs , 1996, Journal of virology.

[43]  María Mercedes Segura,et al.  Canine adenovirus downstream processing protocol. , 2014, Methods in molecular biology.

[44]  P. Alves,et al.  293 cell cycle synchronisation adenovirus vector production , 2009, Biotechnology progress.

[45]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[46]  P. Lio,et al.  Development of a Serum-free Suspension Process for the Production of a Conditionally Replicating Adenovirus using A549 Cells , 2005, Cytotechnology.

[47]  S. Witting,et al.  Vector and helper genome rearrangements occur during production of helper-dependent adenoviral vectors. , 2013, Human gene therapy methods.

[48]  K. Segawa,et al.  Development of novel E1-complementary cells for adenoviral production free of replication-competent adenovirus. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  P. Cruz,et al.  Screening of Novel Excipients for Improving the Stability of Retroviral and Adenoviral Vectors , 2006, Biotechnology progress.

[50]  D. Onions,et al.  Massively parallel sequencing, a new method for detecting adventitious agents. , 2010, Biologicals : journal of the International Association of Biological Standardization.

[51]  María Mercedes Segura,et al.  Advances in helper-dependent adenoviral vector research. , 2008, Current gene therapy.

[52]  L. Babiuk,et al.  Development of a bovine adenovirus type 3-based expression vector. , 1995, The Journal of general virology.

[53]  J. Nevins.  Mechanism of activation of early viral transcription by the adenovirus E1A gene product , 1981, Cell.

[54]  M. Haury,et al.  The importance of 293 cell cycle phase on adenovirus vector production , 2006 .

[55]  P. Stewart,et al.  Role of αv Integrins in Adenovirus Cell Entry and Gene Delivery , 1999, Microbiology and Molecular Biology Reviews.

[56]  C. Scandella,et al.  Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. , 1995, Human gene therapy.

[57]  P. Hearing,et al.  Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection , 1989, Journal of virology.

[58]  A. Turnell,et al.  Adenovirus E1A: remodelling the host cell, a life or death experience , 2001, Oncogene.

[59]  J. Files,et al.  A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. , 2002, Human gene therapy.

[60]  S. Shukla,et al.  Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. , 2005, Biochemical and biophysical research communications.

[61]  R. K. Evans,et al.  Development of stable liquid formulations for adenovirus-based vaccines. , 2004, Journal of pharmaceutical sciences.

[62]  A. Kamen,et al.  Production of adenovirus vector for gene therapy. , 2003, Biotechnology advances.

[63]  M. Imperiale,et al.  Biology of adenovirus and its use as a vector for gene therapy. , 2004, Human gene therapy.

[64]  P. Alves,et al.  Impact of E1 and Cre on Adenovirus Vector Amplification: Developing MDCK CAV-2-E1 and E1-Cre Transcomplementing Cell Lines , 2013, PloS one.

[65]  P. Alves,et al.  Effect of re-feed strategies and non-ammoniagenic medium on adenovirus production at high cell densities. , 2005, Journal of biotechnology.

[66]  G. Kobinger,et al.  Generation of an adenoviral vaccine vector based on simian adenovirus 21. , 2006, The Journal of general virology.

[67]  A. D. De Groot,et al.  A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells. , 2007, Vaccine.

[68]  M. Cotten,et al.  Defining CAR as a cellular receptor for the avian adenovirus CELO using a genetic analysis of the two viral fibre proteins. , 2001, The Journal of general virology.

[69]  P. Working,et al.  Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses , 2005, Oncogene.

[70]  J. Prieto,et al.  Self-inactivating helper virus for the production of high-capacity adenoviral vectors , 2011, Gene Therapy.

[71]  G. Nemerow,et al.  Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.

[72]  M. Weitzman.  Functions of the adenovirus E4 proteins and their impact on viral vectors. , 2005, Frontiers in bioscience : a journal and virtual library.

[73]  S. Salinas,et al.  An Update on Canine Adenovirus Type 2 and Its Vectors , 2010, Viruses.

[74]  W. Russell,et al.  Update on adenovirus and its vectors. , 2000, The Journal of general virology.

[75]  John O. Konz,et al.  Production and formulation of adenovirus vectors. , 2005, Advances in biochemical engineering/biotechnology.

[76]  G. Both,et al.  Construction and transfection of ovine adenovirus genomic clones to rescue modified viruses. , 1996, Virology.

[77]  A. Helenius,et al.  The role of the nuclear pore complex in adenovirus DNA entry , 1997, The EMBO journal.

[78]  M. Perrier,et al.  Low‐protein medium affects the 293SF central metabolism during growth and infection with adenovirus , 2002, Biotechnology and bioengineering.

[79]  F. Graham,et al.  Cre Levels Limit Packaging Signal Excision Efficiency in the Cre/loxP Helper-Dependent Adenoviral Vector System , 2002, Journal of Virology.

[80]  M. Kaleko,et al.  Development of adenovirus serotype 35 as a gene transfer vector. , 2003, Virology.

[81]  Matthew M. Olsen,et al.  Perfusion cultures of human tumor cells: a scalable production platform for oncolytic adenoviral vectors , 2004, Biotechnology and bioengineering.

[82]  P. Alves,et al.  Rational design and optimization of downstream processes of virus particles for biopharmaceutical applications: current advances. , 2011, Biotechnology advances.

[83]  K. Spindler,et al.  Mouse adenovirus (MAV-1) expression in primary human endothelial cells and generation of a full-length infectious plasmid , 1999, Gene Therapy.

[84]  Hanns Lochmüller,et al.  Emergence of Early Region 1-Containing Replication-Competent Adenovirus in Stocks of Replication-Defective Adenovirus Recombinants (ΔE1 + ΔE3) During Multiple Passages in 293 Cells , 1994 .

[85]  W. Vandertop,et al.  Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. , 2002, Cancer research.

[86]  M. Cotten,et al.  Mutational Analysis of the Avian Adenovirus CELO, Which Provides a Basis for Gene Delivery Vectors , 1999, Journal of Virology.

[87]  R. M. Burnett,et al.  Replication-Defective Vector Based on a Chimpanzee Adenovirus , 2001, Journal of Virology.

[88]  K. Mazouni,et al.  Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder. , 2012, Gene.

[89]  D. Brough,et al.  Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo , 1997, Journal of virology.

[90]  R. Gaynor,et al.  Cis-acting induction of adenovirus transcription , 1983, Cell.

[91]  W. Arnold,et al.  Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle , 2000, Gene Therapy.

[92]  S. Kochanek,et al.  A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. , 2002, Human gene therapy.

[93]  María Mercedes Segura,et al.  Chromatography purification of canine adenoviral vectors. , 2012, Human gene therapy methods.

[94]  C. Chavarie,et al.  Improvement of recombinant protein production with the human adenovirus/293S expression system using fed-batch strategies. , 2000, Biotechnology and bioengineering.

[95]  J. Nevins,et al.  Common control of the heat shock gene and early adenovirus genes: evidence for a cellular E1A-like activity , 1984, Molecular and cellular biology.

[96]  L. Johnson,et al.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy , 2000, Nature Medicine.

[97]  O. Danos,et al.  Canine Adenovirus Type 2 Attachment and Internalization: Coxsackievirus-Adenovirus Receptor, Alternative Receptors, and an RGD-Independent Pathway , 2000, Journal of Virology.

[98]  M. Schmitz,et al.  The dual effect of adenovirus type 5 E1A 13S protein on NF-kappaB activation is antagonized by E1B 19K , 1996, Molecular and cellular biology.

[99]  P. Robbins,et al.  Human adenovirus type 35: nucleotide sequence and vector development , 2003, Gene Therapy.

[100]  V. Sandig,et al.  Development and Assessment of Human Adenovirus Type 11 as a Gene Transfer Vector , 2005, Journal of Virology.

[101]  James M. Wilson,et al.  Rescue of chimeric adenoviral vectors to expand the serotype repertoire , 2007, Journal of Virological Methods.

[102]  Hildegund C.J. Ertl,et al.  Adenoviruses as vaccine vectors , 2004, Molecular Therapy.

[103]  S. Korsmeyer,et al.  The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[104]  M. Sousa,et al.  Scalable production of adenovirus vectors. , 2014, Methods in molecular biology.

[105]  M. Lock,et al.  Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. , 2004, Human gene therapy.

[106]  C. Brosnan,et al.  Mouse adenovirus type-1 replication is restricted to vascular endothelium in the CNS of susceptible strains of mice. , 1998, Virology.

[107]  S. Kuriyama,et al.  Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. , 1998, Anticancer research.

[108]  M. Croyle,et al.  Development of formulations that enhance physical stability of viral vectors for gene therapy , 2001, Gene Therapy.

[109]  F. Graham,et al.  A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging , 1997, Journal of virology.

[110]  Julian R. E. Davis,et al.  Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination , 2001, Nature Biotechnology.

[111]  S. Harvey,et al.  Monitoring Adenovirus Infections with On‐Line and Off‐Line Methods , 2000, Biotechnology progress.

[112]  C. Yun,et al.  Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers , 2013, Cancer Gene Therapy.

[113]  Hong Zhang,et al.  Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. , 2001, Cancer research.

[114]  Berk Aj.  Functions of adenovirus E1A. , 1986 .

[115]  John O. Konz,et al.  Development of a novel adenovirus purification process utilizing selective precipitation of cellular DNA. , 2005, Biotechnology and bioengineering.

[116]  Jules Thibault,et al.  High‐Titer Adenovirus Vector Production in 293S Cell Perfusion Culture , 2004, Biotechnology progress.

[117]  E. Kremer,et al.  Long‐term in vivo transduction of neurons throughout the rat central nervous system using novel helper‐dependent CAV‐2 vectors , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[118]  M. Perrier,et al.  Identification of critical infection parameters to control helper-dependent adenoviral vector production. , 2009, Journal of biotechnology.

[119]  M. Lusky,et al.  Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. , 2000, Human gene therapy.

[120]  S. W. Kim,et al.  Evolution of oncolytic adenovirus for cancer treatment. , 2012, Advanced drug delivery reviews.

[121]  J. Bristol,et al.  In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[122]  J. Maizel,et al.  The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. , 1974, Virology.

[123]  E Falkner,et al.  Serum free cell culture: the free access online database. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[124]  I. Kovesdi,et al.  Adenoviral Producer Cells , 2010, Viruses.

[125]  M. Ramachandra,et al.  Matching complementing functions of transformed cells with stable expression of selected viral genes for production of E1-deleted adenovirus vectors. , 2006, Virology.

[126]  John J. Rux,et al.  Structure-Based Identification of a Major Neutralizing Site in an Adenovirus Hexon , 2006, Journal of Virology.

[127]  K. Hehir,et al.  Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence , 1996, Journal of virology.

[128]  M. Havenga,et al.  Challenges in manufacturing adenoviral vectors for global vaccine product deployment. , 2014, Human gene therapy.

[129]  M. Perrier,et al.  An efficient and scalable process for helper‐dependent adenoviral vector production using polyethylenimine‐adenofection , 2009, Biotechnology and bioengineering.

[130]  R. Alemany,et al.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. , 2014, Human gene therapy.

[131]  S. Mittal,et al.  Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. , 2005, Biochemical and biophysical research communications.

[132]  B. J. Dovey-Hartman,et al.  The use of field emission scanning electron microscopy to assess recombinant adenovirus stability. , 2002, Human gene therapy.

[133]  O. Danos,et al.  Canine Adenovirus Vectors: an Alternative for Adenovirus-Mediated Gene Transfer , 2000, Journal of Virology.

[134]  D. Farson,et al.  Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector , 1997, Gene Therapy.

[135]  A. Hyatt,et al.  Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences. , 1997, Virology.

[136]  S. Kostense,et al.  Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.

[137]  Rui Oliveira,et al.  Improving baculovirus production at high cell density through manipulation of energy metabolism. , 2010, Metabolic engineering.

[138]  L. Babiuk,et al.  Development of porcine adenovirus-3 as an expression vector. , 1999, The Journal of general virology.

[139]  S. Kochanek,et al.  Adenovirus vector production and purification. , 2010, Current gene therapy.

[140]  L. Babiuk,et al.  Porcine adenovirus-3 as a helper-dependent expression vector. , 1999, The Journal of general virology.

[141]  K. Kissa,et al.  Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[142]  P. Alves,et al.  Bioprocess development for canine adenovirus type 2 vectors , 2012, Gene Therapy.